Oncotype DX: Scientific Publications and Presentations
ثبت نشده
چکیده
403 Assay result variability during determination of mismatch repair deficiency status using immunohistochemistry: A transatlantic comparative study. Hutchins G., Gray G., Quirke P. Abstract #491 Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on qualityadjusted life expectancy and costs. Meropol N.J., Lyman G.H., Chien R., Hornberger J.C.491 Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on qualityadjusted life expectancy and costs. Meropol N.J., Lyman G.H., Chien R., Hornberger J.C. Abstract #526 Reproducibility of colon tumor grade and relationship to recurrence in the context of clinical, pathologic, and genomic tumor features in 504 patients with stage II colon cancer treated with surgery alone at the Cleveland Clinic. Lavery I.C., Clark-Langone K., Lee M.526 Reproducibility of colon tumor grade and relationship to recurrence in the context of clinical, pathologic, and genomic tumor features in 504 patients with stage II colon cancer treated with surgery alone at the Cleveland Clinic. Lavery I.C., Clark-Langone K., Lee M. 2010 European Society for Medical Oncology (ESMO) Milan, Italy. Abstract #83PD Considerations in the development and validation of genomic tests for cancer recurrence. Kerr DJ, O’Connell MJ, Lavery IC, et al.83PD Considerations in the development and validation of genomic tests for cancer recurrence. Kerr DJ, O’Connell MJ, Lavery IC, et al. 2010 American Society of Clinical Oncology (ASCO) Chicago, IL. Abstract #3503 Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. O’Connell MJ, Lavery IC, Gray R, et al.3503 Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. O’Connell MJ, Lavery IC, Gray R, et al. 2010 Society of Surgical Oncology (SSO) St Louis, MO. Abstract #P162 Number of nodes examined and the 12 gene colon cancer recurrence score predict recurrence in stage II colon cancer in two independent studies. Lavery IC, O'Connell MJ, Lopatin M, et al.P162 Number of nodes examined and the 12 gene colon cancer recurrence score predict recurrence in stage II colon cancer in two independent studies. Lavery IC, O'Connell MJ, Lopatin M, et al. 2010 American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI) Orlando, FL. Abstract #331 Correlation of number of nodes examined and the 12-gene colon cancer recurrence score with recurrence in stage II colon cancer patients from QUASAR Gray RG, Quirke P, Handley K, et al.331 Correlation of number of nodes examined and the 12-gene colon cancer recurrence score with recurrence in stage II colon cancer patients from QUASAR Gray RG, Quirke P, Handley K, et al. Abstract #280 Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. O’Connell MJ, Lavery IC, Gray RG, et al.280 Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. O’Connell MJ, Lavery IC, Gray RG, et al. 2009 American Society of Clinical Oncology (ASCO) Orlando, FL. Abstract #4000 A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively-designed QUASAR validation study. Kerr D, Gray R, Quirke P, et al.4000 A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively-designed QUASAR validation study. Kerr D, Gray R, Quirke P, et al. 2008 American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI) Orlando, FL. Abstract #301 Relationship between tumor gene expression and recurrence in patients with stage II/III colon cancer treated with surgery + 5-FU/LV in NSABP C-06: Consistency of results with two other independent studies. O’Connell MJ, Yothers G, Paik S, et al.301 Relationship between tumor gene expression and recurrence in patients with stage II/III colon cancer treated with surgery + 5-FU/LV in NSABP C-06: Consistency of results with two other independent studies. O’Connell MJ, Yothers G, Paik S, et al. Abstract #302 Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. Lavery I, Hammel J, Cowens JW, et al.302 Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. Lavery I, Hammel J, Cowens JW, et al. 2006 American Society of Clinical Oncology (ASCO) Atlanta, GA. Abstract #3518 Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. O’Connell MJ, Paik S, Yothers G, et al.3518 Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. O’Connell MJ, Paik S, Yothers G, et al.
منابع مشابه
Association Between Oncotype DX Recurrence Score and Clinicopathological Variables in Breast Cancer Patients
Introduction: Breast cancer is the most common cancer and the leading cause of cancer-related death in women. Clinicopathological variables are important factors in deciding on breast cancer treatment. This study evaluated the association between the recurrence score generated by the Oncotype DX® 21-gene assay and classic clinicopathological variables. Methods: A single-institution retrospect...
متن کاملRapid Health Technology Assessment of Oncotype DX in Patients with Early-Stage Breast Cancer
Introduction: Breast cancer is the most common cancer in women. Patients are treated with chemotherapy initially, and if not chemically treated, the risk of recurrence of the disease increases yearly. Therefore, methods for identifying patients for whom chemotherapy would be most beneficial are very important. The Oncotype DX test is a prognostic assay that predicts the likelihood of breast can...
متن کاملClinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence ...
متن کاملCost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
PURPOSE To compare the cost-effectiveness of the tumor subtyping assays Mammostrat® and Oncotype DX® for assessing risk of recurrence in early-stage breast cancer and the potential benefit of adjuvant chemotherapy. METHODS Cost-effectiveness analysis from a US third-party payer perspective. A 10 year Markov model was developed to estimate costs and effects of using each method of risk assessm...
متن کاملGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
UNLABELLED In February 2010, the Medical Advisory Secretariat (MAS) began work on evidence-based reviews of published literature surrounding three pharmacogenomic tests. This project came about when Cancer Care Ontario (CCO) asked MAS to provide evidence-based analyses on the effectiveness and cost-effectiveness of three oncology pharmacogenomic tests currently in use in Ontario.Evidence-based ...
متن کاملOncotype Dx Results in Multiple Primary Breast Cancers
PURPOSE To determine whether multiple primary breast cancers have similar genetic profiles, specifically Oncotype Dx Recurrence Scores, and whether obtaining Oncotype Dx on each primary breast cancer affects chemotherapy recommendations. METHODS A database of patients with hormone receptor-positive, lymph node-negative, breast cancer was created for those tumors that were sent for Oncotype Dx...
متن کامل